Observational Study in Patients With HIV Infection Type 1 After Switching to a Viramune®-Containing Therapy Regimen

Collecting Data in Patients With HIV Infection Type 1 After Switching From a Protease Inhibitor-containing Therapy Regimen and a Viral Load Below Detection Level to a Viramune®-Containing Therapy Regimen

Observational study to collect data on maintaining anti-retroviral activity (quantitative HIV RNA determination) and immunological activity (CD4 cells) despite switching from protease inhibitor to nonnucleoside reverse transcriptase inhibitor (NNRTI) (Viramune®).

Inclusion Criteria:

• Adult male or female patients with HIV type 1 infection

Exclusion Criteria:

• Counter-indications according to summary of product characteristics (SPC) for Viramune tablets
• No persons under 18
• Pregnancy and breast-feeding
• Use of oral contraceptives
• Use of drugs affecting CYP450 3A metabolism